Cargando…
In vitro and in vivo effects of Ambroxol chaperone therapy in two Italian patients affected by neuronopathic Gaucher disease and epilepsy
Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder caused by mutations in the acid β-glucosidase encoding gene (GBA1), resulting in the deficient activity of acid β-glucosidase (GCase). To date, there is no approved treatment for the neurological manifestations of the disease....
Autores principales: | Ciana, Giovanni, Dardis, Andrea, Pavan, Eleonora, Da Riol, Rosalia Maria, Biasizzo, Jessica, Ferino, Dania, Zanatta, Manuela, Boni, Antonella, Antonini, Luisa, Crichiutti, Giovanni, Bembi, Bruno |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691604/ https://www.ncbi.nlm.nih.gov/pubmed/33294373 http://dx.doi.org/10.1016/j.ymgmr.2020.100678 |
Ejemplares similares
-
Ambroxol chaperone therapy for neuronopathic Gaucher disease: A pilot study
por: Narita, Aya, et al.
Publicado: (2016) -
The definition of neuronopathic Gaucher disease
por: Schiffmann, Raphael, et al.
Publicado: (2020) -
Exploring the Pathophysiologic Cascade Leading to Osteoclastogenic Activation in Gaucher Disease Monocytes Generated via CRISPR/Cas9 Technology
por: Ormazabal, Maximiliano Emanuel, et al.
Publicado: (2023) -
Chronic pain in Gaucher disease: skeletal or neuropathic origin?
por: Devigili, Grazia, et al.
Publicado: (2017) -
Neuronopathic Gaucher disease: Beyond lysosomal dysfunction
por: Arévalo, Nohela B., et al.
Publicado: (2022)